Aragen Life Sciences to Invest $30 Million for New Biologics Manufacturing Facility in India

Specifications:

Name:

Aragen Life Sciences to Invest $30 Million for New Biologics Manufacturing Facility in India

Location:

Bangalore, India

Company:

Aragen Life Sciences

Estimated Cost:

$30 Million

Source:

https://www.aragen.com/

Introduction:

Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics announced that it was setting up a new biologics manufacturing facility in Bangalore, India.

Features:

The state-of-the-art facility is part of a $30m investment, spanning nearly 160,000 sqm, and includes process development labs and multiple GMP manufacturing suites with supporting functions like quality control labs (analytical and microbiology). The manufacturing suites will be equipped for intensified processing using single-use bioreactors and advanced downstream purification capability to serve it’s rapidly expanding biologics customer base.   

The facility will offer integrated solutions from process development, process validation, analytical development, pilot production, large-scale DS manufacturing and stability services. It will have the capability to develop and manufacture mAbs, therapeutic proteins and fusion proteins to augment the company’s bioproduction capability in California.

The process development laboratory is scheduled to be operational by the third quarter of FY 24 while the first manufacturing suite will open in the third quarter of FY 25. The facility is designed to include plasmid DNA, mRNA, cell and gene therapy, microbial manufacturing and additional GMP manufacturing suites in the future as demand ramps up.